Pieris Pharma

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZeneca to purchase $10 million equity stake in Pieris common stock as part of an amended collaboration agreement $13 million equity investment by Seagen in Pieris, in addition to a clinical trial and supply agreement to evaluate cinrebafusp alfa (PRS-343) in combination with TUKYSA® (tucatinib) in HER2-low gastric cancer as part of an amended collaboration agreement Additional clinical benefit and safety data from the highest dose cohort and updated biomarker data across all active dose cohorts from cinrebafusp alfa phase 1 monotherapy study to be presented at American Association for Cancer Research Annual Meeting 2021 Synergistic preclinical PRS-344 data to be presented at American Association for Cancer Research Annual Meeting 2021, including in vitro data evaluating potential effects of combining 4-1BB with PD-L1 and the effects of PRS-344 on CD8+ T cells, as well as dose-dependent anti-tumor response in in vivo preclinical models BOSTON, MA / ACCESSWIRE / March 30, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the fiscal year ended December 31, 2020 and provided an update on the Company's recent and anticipated future developments. "We are pleased to announce the achievement of our second clinical milestone for PRS-060/AZD1402, triggered by the initiation of phase 2a by our partner, AstraZeneca, who further demonstrated their commitment to our respiratory-focused alliance with an equity investment," said Stephen S.

Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update

On Tuesday, March 30, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Pieris Pharmaceuticals's Earnings Outlook

The stock price of Pieris Pharmaceuticals Inc (NASDAQ: PIRS) increased by over 10% pre-market. This is why it happened.

PIRS Stock Price Increases Over 10% Pre-Market: Why It Happened

Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercised Seagen to purchase $13 million equity stake in Pieris common stock BOSTON, MA / ACCESSWIRE / March 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that Seagen has made a strategic equity investment in Pieris as part of an ongoing collaboration between the companies. In addition, the companies have entered into a clinical trial collaboration agreement to evaluate the safety and efficacy of combining Pieris' cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, with Seagen's TUKYSA® (tucatinib), a small-molecule tyrosine kinase HER2 inhibitor, for the treatment of gastric cancer patients expressing lower HER2 levels (IHC2+/ISH- & IHC1+) as part of the upcoming phase 2 study to be conducted by Pieris.

Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Strategic Equity I

BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2020 investor call on Tuesday, March 30, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.

Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.

FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript

  Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.

Pieris Pharmaceuticals: Q3 Earnings Insights

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call Transcript

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.

Recap: Pieris Pharmaceuticals Q2 Earnings

NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pieris Pharmaceuticals, Inc. - PIRS

Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript

Pieris Pharmaceuticals (PIRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2019 Results - Earnings Call Transcript

Earnings Preview: Pieris Pharmaceuticals (PIRS) Q4 Earnings Expected to Decline

MeiraGTx Holdings plc

Intellia Therapeutics

uniQure

Vertex Pharmaceuticals

Global X Genomics & Biotechnology ETF

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Gene Therapy the Next Best Thing: Here's Why (Revised)

Gene Therapy the Next Best Thing: Here's Why

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q3 2019 Results - Earnings Call Transcript

The stock of Pieris Pharmaceuticals has made a nice move so far in September.

Pieris Pharmaceuticals: Revisiting The Investment Thesis

Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q2 2019 Results - Earnings Call Transcript

Enphase Energy

Qudian

TAL Education Group

Here are four stocks that appear to be at or near a breakout point: Enphase Energy, Inc.

These 4 Charts Are Looking Better And Better

Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Implied Volatility Surging for Pieris Pharmaceuticals (PIRS) Stock Options

Shares have fallen by 30% since my initial and update articles.

Pieris Pharmaceuticals: Cash-Rich, Key Readout Coming

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q1 2019 Results - Earnings Call Transcript

News for Pieris Pharma Stock (PIRS)